Armata Pharmaceuticals Inc (ARMP)
$2.58
+0.01
(+0.39%)▲
Insights on Armata Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.52M → 966.0K (in $), with an average decrease of 36.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -19.84M → -25.02M (in $), with an average decrease of 26.1% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 273.6%
Performance
- $2.57$2.86$2.58
0.39%
Downside
Day's Volatility :10.14%
Upside
9.79%
- $1.07$5.26$2.58
58.53%
Downside
52 Weeks Volatility :79.66%
Upside
50.95%
Returns
| Period | Armata Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -11.38% | 0.0% |
6 Months | 22.38% | 0.0% |
1 Year | 105.6% | 0.0% |
3 Years | -39.06% | -20.1% |
Highlights
Market Capitalization | 89.7M |
Book Value | - $1.56 |
Earnings Per Share (EPS) | -2.2 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1058.8% |
Return On Assets TTM | -21.7% |
Return On Equity TTM | -3439.35% |
Revenue TTM | 4.7M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | 21.4% |
Gross Profit TTM | -29.5M |
EBITDA | -38.7M |
Diluted Eps TTM | -2.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.9 |
EPS Estimate Next Year | -1.3 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.32 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 210.08%
Technicals Summary
Sell
Neutral
Buy
Armata Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Armata Pharmaceuticals Inc | 2.39% | 22.38% | 105.6% | -39.06% | -18.41% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Armata Pharmaceuticals Inc | NA | NA | NA | -1.9 | -34.39 | -0.22 | NA | -1.56 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Armata Pharmaceuticals Inc | Buy | $89.7M | -18.41% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Company Information
c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
Organization | Armata Pharmaceuticals Inc |
Employees | 66 |
CEO | Dr. Mina Pastagia M.D., MS |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$2.58
+0.39%
Keyarch Acquisition Corp
$2.58
+0.39%
Connexa Sports Technologies Inc
$2.58
+0.39%
Us Value Etf
$2.58
+0.39%
First Wave Biopharma Inc
$2.58
+0.39%
Global X Msci Next Emerging
$2.58
+0.39%
Fat Projects Acquisition Corp
$2.58
+0.39%
Ishares Intl Div Growth Etf
$2.58
+0.39%
Corsair Gaming, Inc.
$2.58
+0.39%